Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma HELP
Based on 34,116 articles published since 2008
|||| 19 

These are the 34116 published articles about Melanoma that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
326 Editorial How much of a good thing? What duration for interferon alfa-2b adjuvant therapy? 2012

Tarhini, Ahmad A / Kirkwood, John M. · ·J Clin Oncol · Pubmed #23008298.

ABSTRACT: -- No abstract --

327 Editorial A major player "gets in the act". 2012

Dudley, Mark E. · ·J Immunother · Pubmed #22996364.

ABSTRACT: -- No abstract --

328 Editorial What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma? 2012

Donnelly, Oliver G / Melcher, Alan A / Vile, Richard G / Pulido, Jose. · ·Immunotherapy · Pubmed #22947000.

ABSTRACT: -- No abstract --

329 Editorial It's a small (integrated multidisciplinary) world. 2012

Ronai, Ze'ev. · ·Pigment Cell Melanoma Res · Pubmed #22925721.

ABSTRACT: -- No abstract --

330 Editorial Administration. 2012

McCalmont, Timothy H. · ·J Cutan Pathol · Pubmed #22905685.

ABSTRACT: -- No abstract --

331 Editorial Drug treatment for melanoma: progress, but who pays? 2012

Kefford, Richard F. · ·Med J Aust · Pubmed #22900855.

ABSTRACT: -- No abstract --

332 Editorial The challenge of defining guidelines for sentinel lymph node biopsy in patients with thin primary cutaneous melanomas. 2012

Gershenwald, Jeffrey E / Coit, Daniel G / Sondak, Vernon K / Thompson, John F. · ·Ann Surg Oncol · Pubmed #22868918.

ABSTRACT: -- No abstract --

333 Editorial A house of cards. 2012

McCalmont, Timothy H. · ·J Cutan Pathol · Pubmed #22845657.

ABSTRACT: -- No abstract --

334 Editorial Metal-on-metal hip implants and the risk of cancer. 2012

Rosengren, Bjorn Erik. · ·BMJ · Pubmed #22833625.

ABSTRACT: -- No abstract --

335 Editorial Compare and contrast. 2012

Anonymous2750732. · ·Prescrire Int · Pubmed #22822589.

ABSTRACT: -- No abstract --

336 Editorial Uveal melanoma trapped in the temple of doom. 2012

Shields, Carol L / Ganguly, Arupa / O'Brien, Joan / Sato, Takami / Shields, Jerry A. · ·Am J Ophthalmol · Pubmed #22813447.

ABSTRACT: -- No abstract --

337 Editorial Can we better identify thin cutaneous melanomas that are likely to metastasize and cause death? 2012

Murali, Rajmohan / Scolyer, Richard A / Thompson, John F. · ·Ann Surg Oncol · Pubmed #22777079.

ABSTRACT: -- No abstract --

338 Editorial Skin cancer in skin of color. 2012

Alexis, Andrew F / Rossi, Anthony M. · ·Cutis · Pubmed #22768430.

ABSTRACT: -- No abstract --

339 Editorial Identifying melanomas in primary care: can we do better? 2012

Newton-Bishop, Julia / Lorigan, Paul. · ·BMJ · Pubmed #22763394.

ABSTRACT: -- No abstract --

340 Editorial When transgenes shape immunity: cancer immune-gene therapy. 2012

Bonini, Chiara / Parmiani, Giorgio. · ·J Gene Med · Pubmed #22736622.

ABSTRACT: -- No abstract --

341 Editorial Just listen and think. 2012

Redberg, Rita F. · ·Arch Intern Med · Pubmed #22732743.

ABSTRACT: -- No abstract --

342 Editorial Warp, weft, and the tapestry of nature. 2012

Arnheiter, Heinz. · ·Pigment Cell Melanoma Res · Pubmed #22712569.

ABSTRACT: -- No abstract --

343 Editorial Stage IV melanoma. 2012

Porensky, Paul / Chiocca, E Antonio. · ·J Neurosurg · Pubmed #22702483.

ABSTRACT: -- No abstract --

344 Editorial Ipilimumab for advanced metastatic melanoma. 2012

Starz, Hans. · ·Expert Opin Biol Ther · Pubmed #22690756.

ABSTRACT: -- No abstract --

345 Editorial Promises from trametinib in RAF active tumors. 2012

Sausville, Edward A. · ·N Engl J Med · Pubmed #22663012.

ABSTRACT: -- No abstract --

346 Editorial Surgery for distant metastatic melanoma improves survival. 2012

Kroon, Bin B R. · ·Ann Surg Oncol · Pubmed #22588471.

ABSTRACT: -- No abstract --

347 Editorial The role of BRAF V600 mutation in melanoma. 2012

Ascierto, Paolo A / Kirkwood, John M / Grob, Jean-Jacques / Simeone, Ester / Grimaldi, Antonio M / Maio, Michele / Palmieri, Giuseppe / Testori, Alessandro / Marincola, Francesco M / Mozzillo, Nicola. ·Department of Melanoma, Istituto Nazionale Tumori Fondazione G, Pascale, Naples, Italy. paolo.ascierto@gmail.com ·J Transl Med · Pubmed #22554099.

ABSTRACT: BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. The first selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared to dacarbazine in a phase III trial in treatment-naïve patients (BRIM-3). The study results showed a relative reduction of 63 % in risk of death and 74 % in risk of tumor progression. Considering all trials so far completed, median overall survival reached approximately 16 months for vemurafenib compared to less than 10 months for dacarbazine treatment. Vemurafenib has been extensively tested on melanoma patients expressing the BRAFV600E mutated form; it has been demonstrated to be also effective in inhibiting melanomas carrying the V600K mutation. In 2011, both FDA and EMA therefore approved vemurafenib for metastatic melanoma carrying BRAFV600 mutations. Some findings suggest that continuation of vemurafenib treatment is potentially beneficial after local therapy in a subset of patients with disease progression (PD). Among who continued vemurafenib >30 days after local therapy of PD lesion(s), a median overall survival was not reached, with a median follow-up of 15.5 months from initiation of BRAF inhibitor therapy. For patients who did not continue treatment, median overall survival from the time of disease progression was 1.4 months. A clinical phase I/II trial is evaluating the safety, tolerability and efficacy of vemurafenib in combination with the CTLA-4 inhibitor mAb ipilimumab. In the BRIM-7 trial vemurafenib is tested in association with GDC-0973, a potent and highly selective inhibitor of MEK1/2. Preliminary data seem to indicate that an additional inhibitor of mutated BRAF, GSK2118436, might be also active on a wider range of BRAF mutations (V600E-K-D-R); actually, treatment with such a compound is under evaluation in a phase III study among stage III-IV melanoma patients positive for BRAF mutations. Overall, BRAF inhibitors were well tolerated; common adverse events are arthralgia, rash, fatigue, alopecia, keratoacanthoma or cutaneous squamous-cell carcinoma, photosensitivity, nausea, and diarrhea, with some variants between different inhibitors.

348 Editorial Gender disparities in patients with melanoma: breaking the glass ceiling. 2012

Sondak, Vernon K / Swetter, Susan M / Berwick, Marianne A. · ·J Clin Oncol · Pubmed #22547593.

ABSTRACT: -- No abstract --

349 Editorial Method to our madness or madness in our methods? Pitfalls in trial methodology. 2012

Levine, Mark N / Juergens, Rosalyn. · ·J Clin Oncol · Pubmed #22547587.

ABSTRACT: -- No abstract --

350 Editorial New melanoma treatments: a panacea or a Pandora's box? 2012

Mariwalla, Kavita. · ·Cutis · Pubmed #22530324.

ABSTRACT: -- No abstract --

Back · Next